Abstract:Glucose-6-phosphate dehydrogenase from human erythrocytes shows successive aggregationdissociation equilibria. The effects of salt concentration and pH show that a molecule of 210,000 molecular weight and ~2 0 ,~ of 9.0 S dissociated to a half-molecule of 105,000 molecular weight and S Z O ,~ of 5.6 S. Evidence for this being a discrete dissociation was provided by molecular weight determinations, relation between sedimentation coefficients and molecular weights, and the occurrence of skew patterns a t a parti… Show more
“…The content of G6PD CRM was lower than estimated by the double-antibody radiommunoassay (8), probably because of the higher background of that procedure with respect to the solid-phase radioimmunoassay. The resulting specific activity in the eight normal subjects reveals a decided similarity to values observed for homogeneous preparations of the B-type enzyme (11,(23)(24)(25)(26).…”
A solid-p ase radioimmunoassay for human glucose-6phosphate dehydrogenase (D-glucose-6-phosphate: NADP+ 1-oxidoreductase; EC 1.1.1.49) was developed that allowed the specific activity of this enzyme protein to be measured in lysates from whole erythrocyte populations, in lysates from erythrocytes of different ages, and in purified samples.
“…The content of G6PD CRM was lower than estimated by the double-antibody radiommunoassay (8), probably because of the higher background of that procedure with respect to the solid-phase radioimmunoassay. The resulting specific activity in the eight normal subjects reveals a decided similarity to values observed for homogeneous preparations of the B-type enzyme (11,(23)(24)(25)(26).…”
A solid-p ase radioimmunoassay for human glucose-6phosphate dehydrogenase (D-glucose-6-phosphate: NADP+ 1-oxidoreductase; EC 1.1.1.49) was developed that allowed the specific activity of this enzyme protein to be measured in lysates from whole erythrocyte populations, in lysates from erythrocytes of different ages, and in purified samples.
“…Further purification of glucose-6-phosphate dehydrogenase was achieved using DEAE-Sephadex a t pH 6.5 and CM-Sephadex a t pH 5.8 in phosphate, with the buffer conditions as previously described [ 5 ] . These steps were carried out in a single day using 12.5-cm Buchner funnels for the separation.…”
Section: Further Purification Of Glucose-6-phosphate Dehydrogenase Amentioning
confidence: 99%
“…The procedure is described according to the steps involved with reference to 6-phosphogluconate dehydrogenase. Glucose-6-phosphate dehydrogenase was separated from 6-phosphogluconate dehydrogenase in step 4 and purified further according to the procedure of Cohen and Rosemeyer [5].…”
Section: Buffers Used In the Purification Proceduresmentioning
confidence: 99%
“…I n the present communication details of a bulk separation procedure are given for a 5000-fold purification yielding 50 mg of enzyme with a specific activity of 10 unitslmg, starting from 70 pints of human blood. The method allowed the concurrent purification of glucose-6-phosphate dehydrogenase, the procedure for which had previously been developed in this laboratory [5].…”
mentioning
confidence: 99%
“…Scheme for purification of 6-phosphoglumte dehydrogenase. The precipitate marked * was used for the purification of glucose-6-phosphate dehydrogenase using the procedure previously reported [5] Eur. J.…”
6-Phosphogluconate dehydrogenase from human erythrocytes has been purified 5000-fold from haemolysates with an overall yield of 60/,.Bulk fractionations followed by gradient elutions were carried out on DEAE-Sephadex and CM-Sephadex, and gel-filtration on Sephadex 6-200. Ammonium sulphate fractionations were used after the CM-Sephadex and Sephadex G-200 steps.The final preparation had a specific activity of 10 units/mg, and was homogeneous on ultracentrifugation. Although other proteins were absent, electrophoresis indicated the presence of isoenzymes. The purification procedure was completed in 3 weeks, and gave 50 mg enzyme from 35 1 blood. The procedure allows the concurrent isolation of glucose-6-phosphate dehydrogenase.The dependence of the enzyme activity on ionic strength, pH and NADPH was investigated. Under cellular conditions the total potential activity is the same for the two hexosemonophosphate dehydrogenases. The flow through the pathway would be controlled by the level of NADPH. Although there is data available on red cell glucose-6-phosphate dehydrogenase [4-61 there is a lack of information on 6-phosphogluconate dehydrogenase regarding its cellular concentration, specific activity and its physical and catalytic properties. Knowledge of these factors contribute to a fuller understanding of the functioning of the pentose phosphate pathway in the red cell, possible effects of metabolites, and changes produced by mutant enzymes.The purpose of the present research is to investigate the physical and catalytic properties of the nor-
Glucose-6-phosphate dehydrogenase (G6PDH) catalyzes the oxidation of glucose-6-phoshate to 6-phospho-gluconolactone with the concomitant reduction of NADP to NADPH. In solution, the recombinant human G6PDH is known to be active as dimers and tetramers. To distinguish between the kinetic properties of dimers and tetramers of the G6PDH is not trivial. Steady-state kinetic experiments are often performed at low enzyme concentrations, which favor the dimeric state. The present work describes two novel human G6PDH mutants, one that creates four disulfide bonds among apposing dimers, resulting in a 'cross-linked' tetramer, and another that prevents the dimer to dimer association. The functional and structural characterizations of such mutants indicate the tetramer as the most active form of human G6PDH.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.